We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA's Off-Label Delay Not Enough For Big Drugmakers

Law360 (February 7, 2018, 8:26 PM EST) -- The U.S. Food and Drug Administration’s delay of controversial new policies on off-label promotion doesn’t go far enough and should be followed by quick action to erase uncertainty about acceptable marketing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.